Candesartan Cilexetil
- 坎地沙坦酯；TCV-116
| 货号-规格 | 货期 | 价格 | 数量 |
| abs816402-20mg | 1-2周 | ￥607.00 | - + |
| abs816402-50mg | 1-2周 | ￥772.00 | - + |
| abs816402-100mg | 1-2周 | ￥882.00 | - + |
| abs816402-200mg | 1-2周 | ￥1103.00 | - + |
大包装询价| 产品描述 | ||
| 描述 | Candesartan cilexetil (Atacand) is a specific nonpeptide Ang II receptor (ATR) antagonist and the prodrug of candesartan which is an ATR antagonist with an IC50 of 15 µg/kg. Candesartan cilexetil (Atacand) efficacy is entirely due to its active metabolite candesartan (CV-11794) and is dose-dependent over the range of 1–8 mg and its clinical antihypertensive dose is stated to be around 4 mg/day. Candesartan cilexetil (Atacand) is administered as a pro-drug that undergoes activation during gastrointestinal absorption. In clinical trials, candesartan cilexetil (Atacand) has produced a dose-dependent effect when given in dosages of 2-32 mg/day. Observed trough-to-peak blood pressure ratios support a once-daily dosage regimen. The antihypertensive effect of candesartan cilexetil (Atacand) 4-16 mg/day was as great as that of enalapril 10-20 mg/day and amlodipine 5 mg/day and larger than that of losartan potassium 50 mg/day. Adding candesartan cilexetil (Atacand) to hydrochlorothiazide 12.5-25 mg/day and amlodipine 5 mg/day led to enhanced blood-pressure reductions and was well tolerated. | |
| 纯度 | >98% | |
| 储存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. | |
| 基本信息 | ||
| 别名 | 坎地沙坦酯；TCV-116 | |
| 外观 | 白色或类白色粉末 | |
| 可溶性/溶解性 | DMSO ：61.1 mg/mL (100 mM) | |
| 生物活性 | ||
| 靶点 | Ang II receptor | |
| In vitro(体外研究) | Candesartan blocks the effects of angiotensin II at the angiotensin II type 1 (AT1) receptor. Candesartan cilexetil is a prodrug that is activated to candesartan by ester hydrolysis during gastrointestinal absorption. | |
| In vivo(体内研究) | Candesartan improves the functional markers in a dose-dependent manner and also upregulates Ang (1-7), ACE2 and mas1 in the myocardium of DCM rats. Candesartan reduces various ER stress and apoptosis markers and the number apoptotic cells in the Candesartan treated rats. Candesartan cilexetil shows angiotensin-II blocking action in a dose-dependent manner in rats with dilated cardiomyopathy. Candesartan cilexetil reduces the left ventricular end-diastolic pressure and heart weight/body weight ratio, the area of myocardial fibrosis and expressions of transforming growth factor-beta1 and collagen-III mRNA. Candesartan cilexetil (1 mg/kg, p.o.) and enalapril (10 mg/kg, p.o.) reduces blood pressure to the same extent 5 hours after administration on the 1st and the 7th day. Candesartan cilexetil significantly increases renal blood flow without any changes in the cardiac index. TCV-116 and enalapril also tends to increase splanchnic blood flow following the 1st dose but not the 7th dose. Candesartan cilexetil is absorbed from the small intestine and hydrolyzed completely to the pharmacologically active metabolite M-I during absorption process. | |
| 温馨提示：本产品仅作科研实验使用，不支持临床等研究 |
- 实验方法 实验条件
共 0 张，还能上传 8 张 提交
- 提示： 尊敬的客户您好，如果您对我们的产品有什么疑问或想要了解的，可以点击“我要咨询”按钮填写您的疑问。
提交不成功？请联系info@absin.cn。
Certificate of Analysis(COA)
促销资讯 更多
危险品化学品经营许可证(不带存储) 许可证编号：沪(浦)应急管危经许[2022]202585(YS)
营业执照(三证合一)